Lilly says Mounjaro and Zepbound sales grew by at least 110% as stock rallies
Why it matters
Eli Lilly reported significant growth in sales of its diabetes medications Mounjaro and Zepbound, with a 110% increase, and also highlighted strong growth for 2026, leading to a stock rally.
Expected market reaction
Market impact analysis based on bullish sentiment with 92% confidence.
Evidence trail
Evidence
Source
MarketWatch
Claim
Lilly says Mounjaro and Zepbound sales grew by at least 110% as stock rallies
AI inference
Bullish · 92%
Generated
2026-02-04 12:21
AI provenance
Technical identifiers
- Provider tag
- groq-llama-3.1-8b-instant
- Analysis version
- groq-llama-3.1-8b-instant
- Article id
- 41422
Original source
The drugmaker also detailed strong growth for 2026
Read the full article on MarketWatch
Original article published by MarketWatch on February 4, 2026. Analysis and insights provided by AnalystMarkets AI.